HYPOGLYCEMIA IN PATIENTS WITH COVID-19: A COINCIDENCE OR A TREND?

OBJECTIVE: The aim: The purpose of this work is to analyze the available scientific information on causes and risk factors of hypoglycemia during treatment of patients with COVID-19. PATIENTS AND METHODS: Materials and methods: A search and analysis of full-text articles was carried out in the PubMed, Web of Science, Google Scholar, and Scopus databases. The search was conducted using the keywords: «hypoglycemia in COVID-19 patients¼, «treatment of COVID-19 and hypoglycemia¼ and «COVID-19 vaccination and hypoglycemia¼ from the beginning of the pandemic in December 2019 to July 1, 2022. CONCLUSION: Conclusions: Hypoglycemia can be an incidental clinical finding. But it can also be a natural consequence of treatment if it is carried out without taking into account the possible hypoglycemic effects of drugs and without careful monitoring of the patient's condition. In the case of determining the program of treatment and vaccination against COVID-19 in patients with DM, the known and possible hypoglycemic effects of drugs and vaccines should be taken into account, the level of glycemia should be carefully controlled, and sudden changes in the type and dose of drugs, polypharmacy and the use of dangerous combinations of drugs should be avoided.

ACUTE ISCHEMIC STROKE IN WOMEN: EFFICACY OF THE FREE RADICAL SCAVENGER EDARAVONE.

OBJECTIVE: The aim: To investigate the effectiveness of usage of the free radical scavenger Edaravone in the therapy of women with AIS. PATIENTS AND METHODS: Materials and methods: A prospective study was conducted of 48 women with AIS, divided into two groups. Patients in the first group (n = 36) were treated with edaravone 30 mg twice a day intravenously. Neuroprotectors were not used in the control group (n = 12). Clinical-instrumental and neurological examination (Glasgow scale (SCG), FOUR, NIHSS, and neuronspecific enolase (NSE) levels) were performed on all patients. RESULTS: Results: The mean FOUR score in the 1th group increased from 11.04±0.85 to 15.47±0.63 points against 11.39±0.56 to 13.46±1.49 in the control group (pp<0.05). The level of NSE in control group patients increased 10-fold (from 9.2 to 96.4 ng/ml, p<0.01). Subsequently, there was a rapid decrease in NSE level in 1th group, and in the control group until 10 days of treatment, the level of NSE did not reach the reference values (p p<0.05). CONCLUSION: Conclusions: The introduction of edaravone in women with AIS results in positive results already in the acute period of the disease. The use of edaravon was significantly effective on the FOUR scale and the dynamics of NSE levels.

DIABETES MELLITUS IN COVID-19 PATIENTS: VERDICT OR NOT?

OBJECTIVE: The aim: To investigate the causes of the negative impact of diabetes mellitus co-morbidity on the onset and development of COVID-19 in diabetic patients. PATIENTS AND METHODS: Materials and methods: Electronic databases of MEDLINE and Google Scholar were searched using keyword searches. CONCLUSION: Conclusions: 1. Diabetes mellitus is not a verdict. Diabetic patients can have COVID-19 with the same frequency as other people. And diabetes mellitus co-morbidity does not increase the probability of development COVID-19. 2. Previous diabetes can contribute the complications of COVID-19, patient's severe condition and can increase the mortality. 3. The reasons for the negative results of COVID 19 treatment in patients with diabetes may be: features of autonomic innervation in patients with diabetes, impaired function of pancreatic islet cells due to the influence of SARS-CoV-2, use of some cardiac drugs, expression of inflammatory factors due to infection.